Home > Press > Hyperion Catalysis International, Inc. Concludes a License Agreement and Supply Agreement with Showa Denko K.K.
Abstract:
Hyperion Catalysis International, Inc. (Hyperion) has concluded a patent license agreement and a supply agreement with Showa Denko K.K. (SDK) of Japan. In exchange for certain payments, royalties and other consideration, the patent license agreement provides that SDK will be able to sell carbon nanotube-based products for use within a defined field in plastics under Hyperion's extensive patent portfolio. The supply agreement provides that SDK will purchase Hyperion's FIBRILTM carbon nanotube-based products for resale along with its own line of carbon nanotube-based products. These license and supply agreements will help SDK and Hyperion, the world leaders in carbon nanotube commercial production technology and quality design, to continue and grow their leading positions in the production, distribution and marketing of carbon nanotube-based products. The two companies have also identified other areas of mutual interest and have initiated discussions regarding possible joint R&D projects.
David Wohlstadter, Hyperion's Vice President of Business Development commented on the transaction stating, "We are pleased to have entered into this relationship with Showa Denko, a recognized world leader in the production of unique chemicals and materials. Hyperion is committed to continuing to expand its own sales and provide its customers with its complete carbon nanotube-based product line. We see the arrangement with Showa Denko as an initial strategic step towards leveraging Hyperion's patent portfolio and capitalizing on the ever increasing demand for carbon nanotubes in commercial applications."
####
About Hyperion Catalysis International, Inc. (Hyperion)
Hyperion, which is headquartered in Cambridge Massachusetts, USA, has been manufacturing and selling its FIBRILTM carbon nanotubes for a wide range of applications since 1983. Hyperion’s flagship FIBRIL™ technology is a conductive, multi-walled carbon nanotube, which is based on the pioneering work in the field by Dr. Howard G. Tennent.
Hyperion has devoted substantial resources to developing, improving and patenting the technology related to the manufacture and use of carbon nanotubes in a variety of applications. Hyperion currently has hundreds of issued and pending patents ranging in scope from the production of carbon nanotubes to various current and future commercial applications. Hyperion supplies its FIBRIL™ nanotubes, pre-mixed, in a range of matrices. These nanotube composites are in commercial use in a growing number of automotive, electronics and other applications. The FIBRIL™ nanotubes are used to impart electrical conductivity and other benefits that are related to the unique structure of the nanotubes.
For more information, please click here
Contacts:
Company PR:
Hyperion Catalysis
Patrick Christmas, +1-240-631-2500, ext 3275
or
Agency:
AH&M Marketing Communications
Jim Allison, +1-413-448-2260, ext 25
Copyright © Business Wire 2009
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanotubes/Buckyballs/Fullerenes/Nanorods/Nanostrings
Tests find no free-standing nanotubes released from tire tread wear September 8th, 2023
Detection of bacteria and viruses with fluorescent nanotubes July 21st, 2023
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||